2024 Isatuximab as monotherapy

Isatuximab as monotherapy

Author: iosg

August undefined, 2024

Web9 aug. 2024 · Daratumumab is approved as monotherapy and in combination with IMiD drugs (i.e., lenalidomide or pomalidomide based on the POLLUX, EQUULEUS, and APOLLO trials) or PIs (i.e., bortezomib or carfilzomib based on the CASTOR and CANDOR trials), plus dexamethasone for RRMM patients. Web29 nov. 2024 · Background: Isatuximab (ISA) targets CD38-expressing tumor cells through a combination of activities, including antibody-dependent cellular cytotoxicity, direct pro …

(PDF) A phase 2 study of isatuximab monotherapy in patients with ...

Web7 dec. 2024 · Isatuximab is a monoclonal antibody that binds to a specific epitope on the human cell surface antigen CD38, which is widely and uniformly expressed on myeloma cells. , , Isatuximab has antitumour activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, … Web2 feb. 2024 · Isatuximab is a monoclonal antibody that binds to a specific epitope on CD38. The purpose of the study was to assess the efficacy and safety of isatuximab monotherapy in a phase 2, multicenter, one-arm, open-label study in patients with relapsed or refractory T-ALL or T-LBL (Clinical Trials.gov identifier NCT02999633). chatham county funeral programs

Cells Free Full-Text The Many Facets of CD38 in Lymphoma: …

Web1 jun. 2024 · 8014 Background: Isatuximab (ISA) is an anti-CD38 mAb with potent anti-myeloma effects as monotherapy or together with lenalidomide (Len) + dexamethasone … Web11 dec. 2024 · Sarclisa ® (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed … customised keychain shop near me

Isatuximab Plus Pomalidomide and Dexamethasone Association …

Results from a Phase II Study of Isatuximab As a Single Agent and …

Web4 mrt. 2024 · Patients received isatuximab either as monotherapy (20 mg/kg on days 1, 8, 15, and 22 [once weekly] of cycle 1 followed by 20 mg/kg on days 1 and 15 of subsequent cycles; Isa group) or in combination with dexamethasone (40 mg/d [20 mg/d in patients … Web29 jul. 2024 · Isatuximab Monotherapy The first single-agent isatuximab study was conducted on 84 patients with RRMM who had received a median of 5 (range: 1-13) … chatham county fire permitWeb5 nov. 2024 · Martin et al. (2024) studied ISA as monotherapy in RRMM patients with a median of five prior therapy and observed an ORR of 20 % (n=17) and clinical benefit rate (CBR) of 16.7 % (n=14). For the high-risk cohort, the ORR was 16.7% (3/18), and CBR 27.8% and progression-free survival (PFS) was 2.9 months (95% confidence interval (CI) … customised keycaps

"Web31 aug. 2024 · Monotherapy with the monoclonal antibody isatuximab yielded a disease control rate of 38% in daratumumab-refractory patients with multiple myeloma, according … " - Isatuximab as monotherapy

Isatuximab as monotherapy

Final results of a phase 1b study of isatuximab short-duration fixed ...

Web2 feb. 2024 · Isatuximab is a monoclonal antibody that binds to a specific epitope on CD38. The purpose of the study was to assess the efficacy and safety of isatuximab … WebDimopoulos, M. A., Bringhen, S., Anttila, P. M., Capra, M., Cavo, M., Cole, C. E., … Vij, R. (2024). Isatuximab as monotherapy and combined with dexamethasone in ...

Did you know?

Web15 okt. 2024 · Isatuximab, an anti‐CD38 monoclonal antibody, targets cells that strongly express CD38 including malignant plasma cells. This open‐label, single‐arm, multicenter, … Web1 mei 2024 · In a phase 2 study of isatuximab monotherapy in patients with RRMM and daratumumab-refractory disease, the primary endpoint of overall response rate (ORR) was not met; the disease control rate...

Web15 okt. 2024 · Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with … Web1 okt. 2024 · Isatuximab was administered at 40 mg/kg in four intravenous injections (injections were reliant on the survival of the control group). Vincristine was administered …

Web18 mrt. 2024 · Dara was initially approved in 2015 as monotherapy for the treatment of IMiD and PI–refractory MM, and since then, anti-CD38 antibodies have been approved … Web4 okt. 2024 · Isatuximab (ISA) is another IgG1 κ mAb that binds selectively to a unique epitope on the human CD38 receptor and has anti plasma cells activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of …

Web14 mei 2024 · We report results from part 1 of a Phase 2 study that evaluated the safety and efficacy of isatuximab monotherapy to select the optimal dose and schedule in heavily pretreated patients for use...

Web9 nov. 2024 · Thus, Isatuximab represents a highly promising therapy in type I cryoglobulinemia that could be use as monotherapy. This study is a Phase 2 pilot prospective study of 21 patients with type I cryoglobulinemia treated by Isatuximab. Isatuximab will be given intravenously at 10 mg/kg at day 0, week (W)1, W2, W3, and … chatham county ga 911Web1 mei 2024 · In a phase 2 study of isatuximab monotherapy in patients with RRMM and daratumumab-refractory disease, the primary endpoint of overall response rate (ORR) … customised keyboard singaporeWebIsatuximab is a monoclonal antibody that targets a specific epitope on CD38 and triggers MM cell death via multiple mechanisms. 5-7 Isatuximab-irfc is approved in the USA for … customised key rings australiaWebPhase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in ... below the recommended dose (20 mg/kg), based on prior … customised keychain singaporeWeb15 okt. 2024 · Isatuximab is marketed by the pharmaceutical company Sanofi and belongs to a group of drugs known as monoclonal antibodies, ... (Revlimid®) and dexamethasone … customised kids cushion coversWeb4 mrt. 2024 · 多発性骨髄腫 2024.03.04 2024.03.08 てんしちゃん. 再発難治の多発性骨髄腫患者におけるイサツキシマブ単剤とデキサメタゾン併用療法の比較（Isatuximab as … customised key ringsWeb7 dec. 2024 · showed the combination of isatuximab with pomalidomide (an immunomodulatory drug) resulted in greater direct toxicity and lysis of CD38 multiple … chatham county fire and ems